Note: Descriptions are shown in the official language in which they were submitted.
WO 93/04702 ~ i ~_ ~ j ~ ~ PCT/US92/06429
USE OF GEf~ISIC ACID OR GENTISYL ALCOHOL FOR STABILISING
RADIOLABELED~PEPTIDES AND PROTEINS
~3ACK ROUND OF THE INVENTION
This 'invention relates to stabilizers for
radiopharmaceutical compositions. More particularly,
stabilizers such as gentisic acid and its derivatives,
alone or in combination with other stabilizers, are used to
inhibit autoradiolysis of radiolabeled peptides and
1o proteins.
The number of therapeutic and diagnostic uses of
radiolabeled compositions is continually growing. Such
uses generally involve the introduction of a suitable
radiolabeled composition into a biological subject.
~ Detection and imaging of radioactive emissions may be used
to diagnose and locate the presence of aberrationu,
pathological conditions, and the like. In some cases, the
radiolabeled composition may be designed to locate in or to
seek out specific tissues or biological receptors for the
2o purpose of delivering therapeutic radioactive emissions.
In general, a radiolabeled composition comprises a
radionuclide, a~ carrier agent designed to target the
specific organ of interest, various auxiliary agents which
affix the radionuclide to the carrier, a delivery vehicle,
such as water, suitable for injection into or aspiration by
the patient, physiologic buffers and salts, and the like.
Some radiopharmaceutical preparations are known to
require stabilizers. For example, technetium-99m and
rhenium-186 compositions are unstable in oxygen and require
stabilizers, such as antioxidants or reducing agents, to
maintain the technetium or rhenium in a usable oxidation
state. Typical reducing agents used in technetium-99m and
rhenium-186 compositions include stannous, ferrous, and
chromous salts. Sometimes other additives, such as
ascorbic acid, d-ascorbic acid, gentisic acid, raductia
acid, erythorbic acid, p-aminobenaoic acid, 4-
hydroxybenzoic acid, nicotinic acid, nicotinasida, and 2,5-
WO 93/04702 PCT/US92/06429
i =z.~~..
~.~ . ~ _ ~ r :., j
2
dihydroxy-1,4-benzenedisulfonic acid, are included to
inhibit the oxidation of the radionuclide or the reducing
agent.
Other radionuclides, such as ~~~In, 9°Y, and 6~Ga exist in
a stable oxidation state, and therefore, do not require
stabilizers to maintain their useful oxidation state.
Over the years, there has been growing interest in
preparing radiolabeled proteins such as hormones,
macroaggregated albumin ("MAA"), human serum albumin
("HSA"), monoclonal antibodies, or monoclonal antibody
fragments for the purpose of diagnosing and treating
diseases, such as inflammation, deep vein thrombosis, or
cancer. In some cases, autoradiolysis of the labeled
protein has been observed. To inhibit or prevent
autoradiolysis, experts have suggested adding HSA to the
composition (e. a., R.A.J. Kishore, et al., "Autoradiolysis
of Iodinated Monoclonal Antibody Preparations," Int. J.
Radiat. Agel. Instrum.. Part B, Vol. 13, No. 4, pp. 457-459
(1986)) or keeping the radiopharmaceutical composition
frozen between preparation and administration (ea., R.L.
Wahl, et al., "Inhibition of Autoradiolysis of Radiolabeled
Monoclonal Antibodies by Cryopreservation," J. Nuc. Med.,
Vol. 31, No. 1, pp. 84-89 (1990)). These techniques for
preventing autoradiolysis are often not effective or
practical when used with many radiolabeled peptides and
proteins.
Recently, a number of exciting new peptides for
diagnostic and therapeutic applications have been isolated
and synthetically developed. One such peptide is an
octapeptide somatostatin analog known as octreotide and
described in U.S. Patent No. 4,395,403. Octreotide has a
very high binding affinity to somatostatin receptors in a
variety of human tumors. By linking octreotide to a
suitable chelating agent capable of forming a complex with
radionuclides, it has been possible to create radiolabeled
WO 93/04702 ~ -~ ~ ~ ~ ~ ~ PCT/US92/OG429
3
octreotide which effectively images tumors having
somatostatin receptors. Somatostatin analogs containing
chelating groups are described in UK Patent Publication No.
2,225,579.
Despite the potential usefulness of radiolabeled
peptides, it has been found that they are very susceptible
to autoradiolysis. As used herein, the term autoradiolysis
includes chemical decomposition of the peptide by the
action of radiation emitting from the radioisotope coupled
to the peptide. Some believe autoradiolysis may be caused
by the formation of free radicals, such as hydroxyl
radicals, in the water or delivery vehicle by the radiation
emitted from the radioisotope.
From the foregoing, it will be appreciated that what
is needed in the art are stable radiolabeled peptide and
protein compositions. Thus, it would be a significant
advancement in the art to provide stabilizing agents which
substantially inhibit ~ autoradiolysfs of radiolabeled
peptides and proteins.
Such compositions for substantially inhibiting peptide
and protein autoradiolysis are disclosed and claimed
herein.
~3~U~ARY ~ THE INV NF TION
The present invention provides compositions for
preparing stable radiolabeled peptide and protein
preparations. The stabilizers used in the present
invention are able to substantially inhibit autoradiolysis
of radiolabeled peptides and proteins, It has been found
that stabilizers that are effective at preventing oxidation
of radioisotopes, such as ~'°Tc, are not necessarily
effective at preventing autoradiolysis of peptides and
proteins. Likewise, it has been found that stabilizers and
techniques used to pssusnf autoradiolysis of proteins, such
as addition of HSA or freezing, era not effective or
i
CA 02113995 2002-02-06
WO 93/04702 PGT/US92/06429
4
practical in many cases. Accordingly, the present
invention is directed to compositions containing
stabilizers that substantially inhibit sutoradiolysfs of
peptides and proteins.
Gentisic acid and its derivatives have been found to
be very effective at inhibiting peptide and protein
autoradiolysis. Gentisic acid or its derivatives may also
be used in combination with other stabilizers, such~as
inositol and ascorbic acid, to inhibit autoradiolysis.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to compositions
containing stabilizers that substantially inhibit
autoradiolysfs of peptides and proteins. One class of
stabilizers that is very effective at inhibiting
autoradiolysis of peptides and proteins is gentfsic acid
and its derivatives. The radiolabeled peptides and
proteins for which the stabilizers of the present invention
are needed include peptides and proteins having diagnostic
and therapeutic applications.
Gentisic acid (chemically: 2,5-dihydroxybenzoic acid)
is commercially available and can be prepared by several
methods known in the art. Derivatives of gsntfsic acid
include the pharmaceutically-acceptable salts and esters of
gentisic acid and gentisyl alcohol. Examples of suitable
gentisic acid derivatives are described in U. S. Patent Nos.
4,497,744 and 4,232,000.
Other stabilizers such as inositol and ascorbic acid
inay be used in combination with gentisic acid or its
derivatives to inhibit autoradiolysis of radiolabeled
peptides.
The pharmaceutically-acceptable salts and esters of
gentisic acid and gentisic alcohol can be prepared by
standard neutralization and esterification procedures known
i
CA 02113995 2002-02-06
r
WO 93/04702 PCT/(JS92/06429
in the art, such as the techniques described in U.S. Patent
Nos. 4,497,744 and 4,232,000. In practice, the salts and
esters of gentisic acid suitable for use in the present
invention can be selected according to their solubility.
5 Soluble gentisate salts include the soluble alkali metal,
alkaline earth metal, heavy metal, and ammonium salts. The
alkali metal salts, such as sodium, lithium, and potassium,
are very soluble and are currently preferred. The alkaline
earth metal gentisate salts, such as calcium and magnesium,
are less soluble, but are still suitable for use herein.
The present invention may be used with a wide range of
radioisotopes capable of causing autoradiolysis of
peptides. Such radioisotopes include T-, B-, and a-
emitters.
Suitable 'y-emitters include those radionuclides which
are useful for diagnostic techniques. Examples of some
typical y-emitting radionuclides are "Ga, "'In, ~°'Tc, "'9Yb,
and '~I, 'nI, and ~°'Tl. Examples of possible B-emitting
radionuclides include those which are useful in therapeutic
applications such as 9°Y, "Cu, '"Ra, 'eRe, "'Er, '='Sn, '~'Te,
~4lpr, ~ l9tA~ ~ 104pd ~ I65Dy i 3ZP, n~P~. ~ rnLu, I6bH0 ~ 131Sm ~ 90Y ~ l1l
I .
a9Sr, and '°sRh. Typical a-emitters include ='IBi, ="At, I"Am,
and ~sFm.
Radiolabeling of peptides and proteins can be achieved
using various methods known fn the art. For example,
peptides can be labeled through use of a bifunctional
chalata, direct labeling, or covalent binding to a specific
functional group of an amino acid side chain. The use of
a bifunctional chelate involves covalent attachment of a
chelata, which complexes with the radionuclide, to the
peptide or protein. Possible bifunctional chelates include
DTPA and NHS ligands. The DTPA may be attached to the
peptide or protein by the dicyclic dianhydride method
described in U.S. Patent No. 4,479,930. N3S ligands may be
CA 02113995 2002-10-08
attached to the peptide or protein by the methods described
in t~.S. Patent No. 4,965,392 and European Patent
Publication Number o2sao7~.
In direct labeiing, the radionuclide .binds to the
functiona3 group of amino acid side chain~a present in the
peptide or protein. The radionuclide ray also bind to
reduced fonas of a peptide or protein, such as a peptide or
protein containing a reduced disulfide bond, one example
of direct labeling known in the art is described fn U.8.
I0 Patent No. 4.57,868.
Another well known techniqu~ for labeling peptides and
proteins involves covalehtly binding the radionuclide to
one specific functional group of an amino acid aids chat»,
such as incorporation of iodide into the phenol group o! a
tyrosine residue.
commercial products,lor preparing radiopharmaasuticals
are generally provided as lyophilized (freeze-dried) rkits~
or as liguid formulations. Lyophilized kits axe yell known
in tbs art. According to the present invention,
lyophilized kits may contain a transfer liqand, such as
citric acid, acetic acid, or sodium tartrate, a reduci»g
agent, depending on the radioisotope that is ased, a
bulking agent, such as inositol or lactose, the peptide or
protein to be labeled, and one or more gentisic $eid
stabilizers. Additional stabilizers may also be
incorporated into the formulation as describ~ad herein. The
radioisotope is added to the lyophilized kit just prior to
patient administration.
Liquid formulations usually contain the peptide or
3A protein labeled with the radioisotope. According to the
present invention, the liquid formulation also contains one
or more gsntisic acid derivatives to stabilize the
formulation. other stabilizers, such as inositol ani
ascorbic acid, may also be included in the fortaulation to
~5
WO 93/04702 ~. y _~ v rl iJ -~1 PCT/US92/06429
7
improve stability. A surfactant, such as polysorbate 80,
and a salt solution to give a desired ionic strength, may
also be added to improve stability if the solution is
autoclaved. In some cases, the solution may need to be
deoxygenated.
The radiolabeled compositions of the invention may be
administered parenterally, preferably intravenously, in the
form of injectable pharmaceutical solutions or suspensions
according to conventional techniques.
Dosages employed in practicing the therapeutic method
of the present invention will of course vary depending on
the particular condition to be treated, for example the
.volume of the tumor, the particular chelate employed, the
half-life of the radioisotope, and the therapy desired. In
general, the dose is calculated on the basis of
radioactivity distribution to each organ and on observed
target uptake.
The following examples are offered to further
illustrate different aspects of the present invention.
These examples are intended to be purely exemplary and
should not be viewed as a limitation on any claimed
embodiment.
Example 7,
Preparation of '"In labeled DTPA-octreotide
with citrate additive.
To a lyophilized kit containing 10 ~Cg DTPA-octreotide
(N-[3,6,9,9-tetrakis(carboxymethyl)-3,6,9-triazanonanoyl)-
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L-
lysyl-L-threonyl-L-hemicystyl-L-threoninol cyclic (2-~7)
disulfide, MW=1394.60 gm/mol), 5.6 mg trisodium citrate
dihydrate, and 0.4 mg citric acid monohydrate was added 1.0
ml of 0.02 M HCl containing 4.70 mCi of "'In. The pH of the
solution was 4.5. The solution was kept at coos
temperature and monitored for the amount of "'In OTPA-
octreotide using reverse-phase HPLC and a Beckman 170
WO 93/04702 PCT/US92/06429
!'d .~ ~1.. :J ~
radiometric detector. The HPLC method used a Hamilton
PRP-1 column, 25 cm x 4.1 mm, 10 microns and a gradient
system, linearly tamping from 100% A (A=10:90
ethanol:water, 10 mM tetrabutyl ammonium phosphate, pH 3)
to 43:57 A:8 (B=50:50 ethanol: water, 10 mM tetrabutyl
ammonium phosphate, pH 3) over 10 minutes, then held at
43:57 A:B for 15 minutes, then linearly tamped to 100% B
over 10 minutes. The flow rate was 1.5 ml/min. The
retention time of "'In DTPA-octreotide was 30 minutes.
The purity of the "'In labeled peptide was 87%
immediately post-reconstitution and 50% at 15 hours post-
reconstitution.
Example 2
greoaration of "'In labeled DTPA-octreotide
~~th citrate and inositol additives.
To a lyophilized kit containing 10 ug DTPA-octreotide
(N-(3,6,9,9-tetrakis(carboxymethyl)-3,6,9-triazanonanoyl)-
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L-
lysyl-L-threonyl-L-hemicystyl-L-threoninol cyclic (2~7)
disulfide, MW=1394.60 gm/mol), 5.6 mg trisodium citrate
dihydrate, 0.4 mg citric acid monohydrate, and 1.0 mg
inositol was added 1.0 ml of 0.02 M HCl containing 6.04 mCi
of "'In. The pH of the solution was 4.5. The solution was
kept at room temperature and monitored for the amount of
"'In DTPA-octreotide using reverse-phase HPLC and a Beckman
170 radiometric detector. The HPLC,method used a Hamilton
PRP-1 column, 25 cm x 4.1 mm, 10 microns and a gradient
system, linearly tamping from 100% A (A=10:90
ethanol:water, 10 mM tetrabutyl ammonium phosphate, pH 3)
to 100% B (B=50:50 ethanol: water, 10 mM tetrabutyl ammonium
phosphate, pH 3) over 60 minutes. The flow rate was 1.5
ml/min. The retention time of '~'In DTPA-octreotide was 44-
45 minutes.
WO 93/04702 J ~ ~~ ~ j ~ ~ j PC'T/US92/06429
9
The purity of the "'In labeled peptide was 94%
immediately post-reconstitution and 73.5% at 24 hours post-
reconstitution.
Example 3
Preparation of ~~~In labeled DTPA-octreotide
_with citrate inositol and ascorbic acid additives.
To a lyophilized kit containing 10 ~g DTPA-octreotide
(N-[3,6,9,9-tetrakis(carboxymethyl)-3,6,9-triazanonanoyl~
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L
lysyl-L-threonyl-L-hemicystyl-L-threoninol cyclic (2-~7)
disulfide, MW=1394.60 gm/mol), 5.6 mg trisodium citrate
dihydrate, and 0.4 mg citric acid monohydrate was added 1.0
.mg inositol, 8.8 mg ascorbic acid, 9.9 mg sodium ascorbate,
and 1.0 ml of 0.02 M HCl containing 5.05 mCi of "'In. The
pH of the solution was 4Ø The solution was kept at roam
temperature and monitored for the amount of "'In DTPA- y
octreotide using reverse-phase HPLC and a Beckman 170
radiometric detector. The HPLC method used a Hamilton
PRP-1 column, 25 cm x 4.1 mm, 10 microns and a gradient
system, linearly ramping from 100% A (A=10:90
ethanol:water, 10 mM tetrabutyl ammonium phosphate, pH 3)
to 100% B (B=50:50 ethanol: water, 10 mM tetrabutyl ammonium
phosphate, pH 3) over 35 minutes. The flow rate was 1.5
ml/min. The retention time of "'In DTPA-octreotide was 30
minutes.
The purity of the ~~iIn labeled peptide was 94%
immediately post-reconstitution and 86% at 22 hours post-
reconstitution.
Example 4
prpn~on Qf ~~~In 1 be ed OTPA-octreotide
t'
To a lyophilized kit containing 10 ~cg DTPA-octreotida
(N-[3,6,9,9-tetrakis(carboxymethyl)-3,6,9-triazanonanoyl~-
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L-
WO 93/04702 PCT/US92/06429
~.a..?_~~'~'j:9
to
lysyl-L-threonyl-L-hemicystyl-L-threoninol cyclic (2-~7)
disulfide, MW=1394.60 gm/mol), 5.6 mg trisodium citrate
dihydrate, and 0.4 mg citric acid monohydrate was added 1.0
mg inositol, 1.5 mg gentisic acid, and 1.0 ml of 0.02 M HCl
containing 5.40 mCi of "'In. The pH of the solution was
4Ø The solution was kept at room temperature and
monitored for the amount of "'In DTPA-octreotide using
reverse-phase HPLC and a Beckman 170 radiometric detector.
The HPLC method used a Hamilton PRP-1 column, 25 cm x 4.1
mm, 10 microns and a gradient system, linearly ramping from
100$ A (A=10:90 ethanol: water, 10 mM tetrabutyl ammonium
phosphate, pH 3) to 100% B (H=50:50 ethanol:water, 10 mM
. tetrabutyl ammonium phosphate, pH 3) over 60 minutes. The
flow rate was 1.5 ml/min. The retention time of "'In DTPA
octreotide was 44-45 minutes.
The purity of the "'In labeled peptide was 94%
immediately post-reconstitution and 94% at 48 hours post-
reconstitution.
Example 5
Preparation of "'In labeled DTPA-octreotide
with ctentisi,g aci additiye.
To a vial containing 10 ~g DTPA-octreotide (N
[3,6,9,9-tetrakis(carboxymethyl)-3,6,9-triazanonanoyl]-D
phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L
lysyl-L-threonyl-L-hemicystyl-L-threoninol cyclic (2-~7j
disulfide, MW=1394.60 gm/mol) in 10 ~l of water was added
1 ml of a degassed stock solution of 2.3 mg gentisic acid
and 41.4 mg sodium gentisate dihydrate and 25 ~l of 0.02 M
HC1 containing 4.66 mCi of "'In. The pH of the solution was
4.2. The solution was kept at room temperature and
monitored for the amount of "'In DTPA-octreotide using
reverse-phase HPLC and a Beckman 170 radiometric detector.
The HPLC method used a Hamilton PRP-1 column, 25 cm x 4.1
mm, 10 microns, eluting with mobile phase A (A=20:10:70
WO 93/04702 c-) .~ ~~ '..~ 1~ Q~ ~~ PCT/US92/06429
l~
11
acetonitrile:ethanol:water, 10 mM tetrabutyl ammonium
phosphate, pH 3) for 9 minutes, then eluting with mobile
phase 8 (8=50:10:40 acetonitrile:ethanol:water, 10 mM
tetrabutyl ammonium phosphate, pH 3) from 9 to 15 minutes.
The flow rate was 1.2 ml/min. The retention time of "'In
DTPA-octreotide was 9-10 minutes.
The purity of the "'In labeled peptide was
immediately post-reconstitution and 97~ at 72 hours post-
reconstitution.
Examplo 6
~i~
To a lyophilized kit containing 10 beg DTPA-octreotide
(N-[3,6,9,9-tetrakis(carboxymethyl)-3,6,9-triazanonanoyl~-
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L-
lysyl-L-threonyl-L-hemicystyl-L-threoninol cyclic (2~7)
disulfide, MW=1394.60 gm/mol) and acetate buffer, pH 4, was
added 12.3 mg nicotinic acid and 1.0 ml of o.02 M HCl
containing 2.45 mCi of "'In. The pH of the solution was
3.8. The solution was kept at room temperature and
monitored for the amount of "'In DTPA-octreotide using
reverse-phase HPLC and a Beckman 170 radiometric detector.
The HPLC method used a Hamilton PRP-1 column, 25 cm x 4.1
mm, 10 microns and a gradient system, linearly camping from
100 A (A=10:90 ethanol: water, 10 mM tetrabutyl ammonium
phosphate, pH 3) to 100 8 (B=50:50 ethanol:water, 10 mM
tetrabutyl ammonium phosphate, pH 3) over 60 minutes. The
flow rate was 1.5 ml/min. The retention time of "'In DTPA
octreotide was 44-45 minutes.
The purity of the "'In labeled peptide was 90t
immediately post-reconstitution and 80~ at 24 hours post-
reconstitution.
WO 93/04702 PCT/US92/06429
.~. ." a ~1 ~~ ~ 12
Example 7
~~~Tr, 7 nE,nlnea (1TD~_
To a lyophilized kit containing 10 ~cg DTPA-octreotide
(N-(3,6,9,9-tetrakis(carboxymethyl)-3,6,9-triazanonanoyl)-
D-phenylalanyl-L-hemicystyl-L-phenylalanyl-D-tryptophyl-L-
lysyl-L-threonyl-L-hemicystyl-L-threoninol cyclic (2-~7)
disulfide, MW=1394.60 gm/mol), 5.6 mg trisodium citrate
dehydrate, and 0.4 mg citric acid monohydrate was added 1.0
mg inositol, 11 mg resorcinol, and 1.0 ml of 0.02 M HCl
containing 5.17 mCi of "'In. The pH of the solution was
4.5. The solution was kept at room temperature and
monitored for the amount of "'In DTPA-octreotide using
.reverse-phase HPLC and a Beckman 170 radiometric detector.
The HPLC method used a Hamilton PRP-1 column, 25 cm x 4.1
mm, 10 microns and a gradient system, linearly tamping from
100% A (A=10:90 ethanol: water, 10 mM tetrabutyl ammonium
phosphate, pH 3) to 43:57 A:B (B=50:50 ethanol:water, 10 mM
tetrabutyl ammonium phosphate, pH 3) over 10 minutes, then
held at 43:57 A:B for 15 minutes, then linearly tamped to
100% 8 over 10 minutes. The flew rate was 1.5 ml/min. The
retention time of "'In DTPA-octreotide was 30 minutes.
The purity of the "'In labeled peptide was 81%
immediately post-reconstitution (also, 6% of an "'In
transfer ligand complex) and 87% at 120 hours post
reconstitution.
The results of Examples 1-7 are summarized in Table 1.
These results demonstrate that gentisic acid, either alone
or in combination with other stabilizers, is very effective
at preventing radiolysis of radiolabeled peptides.
1 n1 s.
WO 93/0:1702 ~, ;_ .i a ~ ~ ~ PCT/US92/06429
13
Table 1
Initial
Example Additives) Purity Stability
1 citrate 87% 50% @ 15 hrs
2 citrate 94% 73.5% @ 24 hrs
inositol
3 citrate 94% 86% @ 22 hrs
inositol
ascorbic acid
4 citrate 94% 94% @ 48 hrs
inositol
gentisic acid
- 5 gentisic acid 97% 97% @ 72 hrs
6 acetate 90% 80% @ 24 hrs
nicotinic acid
7 inositol 87%' 87% @ 120 hrs
resorcinol
~81% "'In DTPA-octreotide and transfer ligand complex.
6%
Example 8
~~_eparation of '~I labeled LFi-RH.
This preparation is done in a well-ventilated fume
hood equipped with a charcoal filter to absorb any volatile
iodine.
In a 1.5 ml polyethylene tube, add 70 ,u1 of buffer A
(A=150 mM sodium phosphate, pH 7.4), 10 u1 of a 0.1 mM
solution of LH-RH (des-gly'°,(D-ala°]-LH-RH ethylamide) in
O.I M acetic acid, and 5 mCi of '~I in 5 ~1 of 0.01 M NaOH.
.The reaction is started by adding 10 ,~l of a chloramine T
solution (0a5 mg chloramine T/ml buffer A) to the peptide
solution and is mixed by cautious aspiration and expulsion
of the reaction mixture with the pipet used to add
chloramine T. After 1 minute, 100 p1 of sodium
metabisulfite solution (1 mg sodium metabisulfite/ml buffer
A) is added to terminate the reaction and the reaction is
CA 02113995 2002-02-06
f
WO 93/04702 PCT/US92/06429
14
mixed with the pipet as explained previously. The reaction
is kept in the hood a few minutes to allow any volatile
iodine to exhaust from the reaction vial into the hood.
The solution is loaded onto a PD-l0 column (G-25M
SephadexT"" PD-10 column; Pharmacia LKH Biotechnology Inc.;
Piscataway, NJ) eluting with PHS, pH 7.4, and 0.5 ml
fractions are collected. The '~I labeled LH-RH is in
fractions 6 and 7, which are subsequently combined. Half
of this solution is transferred to another vial containing
l0 2 mg of gentisic acid.
The '~I LH-RH solutions are kept at room temperature
and monitored for the amount of iodinated peptide and the
amount of free iodide using reverse-phase HPLC and a
Beckman 170 radiometric detector. The HPLC method uses a
Hamilton PRP-3 column, 15 cm x 4.1 mm, 10 microns and a
gradient system eluting from 100 A (A=15:85
acetonitrile:water, 6 mM HCl) to 100 8 (B=50:50
acetonitrile:water, 6 mM HC1) over 30 minutes. Free iodide
elutes at the void volume in this system while the '~I LH-RH
is retained and has a longer retention time. The solution
containing the radiolabeled peptide without the gentisic
acid stabilizer shows evidence of autoradiolytic
degradation by the appearance of an increasing amount of
free iodide in solution, as determined by HPLC analysis.
EBampl~ 9
~p~~,~:ion of '~Re labeled N,,S-NR-Lu-10.
The NR-Lu-10 monoclonal antibody (NeoRx Corporation,
seattle, WAj is labeled with 'eRe using the pre-formed
chelate approach developed by NeoRx and described in U.S.
Patent No. 4,965,392 and European Patent Publication Number
0284071. The ligand used to form the "6Re complex is a
tetrafluorophenyl ester of [N-(S-ethoxyethyl
mercapto)acetyl amino) adipoylglycyl]glycine. The "6Re
complex formed is referred to as a '~Re-N3S complex, since
r
CA 02113995 2002-02-06
- WO 93/04702 PGT/US92/06429
the "~Re is coordinated by the three nitrogens and the one
sulfur atom of the ligand. The "~Re complex is formed by
reducing 0.5 ml of '~Re perrhenate (400 mCi, 4 mCi/ug Re)
contained in a purged 10 ml vial with 0.5 ml of a
5 deoxygenated stock solution of 1 mg stannous chloride, 10
mg gentisic acid, and 250 mg citric acid. The solution is
kept at room temperature for 15 minutes. To this solution
is added o.2 ml of a 1 mg ligand/1 ml isopropanol stock
solution. The solution is heated for 15 minutes at 80°C.
10 A solution of 25 mg of protein in 1.0 ml PBS is added
to the vial containing the 'eRe-NjS complex. The pH of the
solution is adjusted to pH 9-9.5 with a 0.2 M sodium
carbonate buffer. The solution is incubated at room
temperature for 15 minutes. Given a typical conjugation
15 yield of 50~, this reaction yields '~Re-NHS-NR-Lu-10 at a
specific activity of 200 mCi 'eRe/25 mg NR-Lu-10.
The "~Re-NjS-NR-Lu-10 is purified using a PD-10 column
(G-25M SephadexT"" PD-10 column; Pharmacia LKB Biotechnology
Inc.; Piscataway, NJ) eluting with PBS, pH 7.4, collecting
0.5 ml fractions. The 'mRe-N3S-NR-Lu-to elutes in fractions
6 and 7, which are subsequently combined. Half of this
solution is transferred to a vial containing 10 mg of
gentisic acid.
The labeled protein is kept at room temperature and is
monitored for the purity of 'eRe-NHS-NR-Lu-10 using HPLC
with a gel permeation column (zorbax'°GF-250; 9.4 mm x 25.0
cm; DuPont, Wilmington, DE) eluting with 0.1 M phosphate,
0.1~ sodium dodecyl sulfate, pH 6.7 mobile phase at a flow
rate of 1 ml/min. Presence of autoradiolytic decomposition
of the labeled monoclonal antibody is detected by the
appearance of HPLC peaks that do not correspond to that for
the "6Re-NHS-NR-Lu-10 monoclonal antibody. The radiolytic
decomposition occurs in the solution that does not contain
gentisic acid.
35.
WO 93/04702 ~ PCT/US92/06429
..i ~ U
' ~ ~~ .,'.)
The invention may be embodied in other specific forms
without departing from its spirit or essential
characteristics. The described embodiments are to be
considered in all respects only as illustrative and not
restrictive. The scope of the invention is, therefore,
indicated by the appended claims rather than by the
foregoing description. All changes which come within the
meaning and range of equivalency of the claims are to be
embraced within their scope.
What is claimed is:
